Rhumbline Advisers Akero Therapeutics, Inc. Transaction History

Rhumbline Advisers

$113 Billion
Q2 2025

A detailed history of Rhumbline Advisers transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 107,438 shares of AKRO stock, worth $5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

107,438

Previous 110,687 2.94%

Holding current value

$5 Million

Previous $4.48 Million 27.95%

% of portfolio

0.01%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$34.04 - $56.28 $110,595 - $182,853	-3,249 Reduced 2.94%	107,438 $5.73 Million
Q1 2025 Apr 08, 2025	BUY	$21.87 - $57.56 $109,371 - $287,857	5,001 Added 4.73%	110,687 $4.73 Million
Q4 2024 May 29, 2025	SELL	$26.75 - $35.28 $133,776 - $176,435	-5,001 Reduced 4.52%	105,686 $2.94 Million
Q4 2024 Jan 30, 2025	BUY	$26.75 - $35.28 $35,042 - $46,216	1,310 Added 1.26%	105,686 $2.94 Million
Q3 2024 Nov 12, 2024	SELL	$21.45 - $29.34 $63,534 - $86,905	-2,962 Reduced 2.76%	104,376 $2.99 Million
Q2 2024 Aug 01, 2024	BUY	$18.31 - $24.62 $456,651 - $614,022	24,940 Added 30.27%	107,338 $2.52 Million
Q1 2024 May 09, 2024	BUY	$17.76 - $31.18 $207,774 - $364,774	11,699 Added 16.55%	82,398 $2.08 Million
Q4 2023 Feb 08, 2024	SELL	$11.38 - $50.33 $967 - $4,278	-85 Reduced 0.12%	70,699 $1.65 Million
Q3 2023 Nov 09, 2023	BUY	$41.19 - $52.25 $395,835 - $502,122	9,610 Added 15.71%	70,784 $3.58 Million
Q2 2023 Aug 08, 2023	BUY	$36.89 - $56.88 $232,517 - $358,514	6,303 Added 11.49%	61,174 $2.86 Million
Q1 2023 May 11, 2023	BUY	$37.27 - $50.24 $117,698 - $158,657	3,158 Added 6.11%	54,871 $2.1 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $316,074 - $517,969	9,452 Added 22.37%	51,713 $2.83 Million
Q3 2022 Nov 10, 2022	BUY	$10.15 - $34.05 $27,151 - $91,083	2,675 Added 6.76%	42,261 $1.44 Million
Q2 2022 Aug 11, 2022	BUY	$8.0 - $15.01 $105,328 - $197,621	13,166 Added 49.83%	39,586 $374,000
Q1 2022 May 12, 2022	BUY	$12.97 - $22.26 $9,922 - $17,028	765 Added 2.98%	26,420 $375,000
Q4 2021 Feb 10, 2022	SELL	$19.87 - $26.24 $10,849 - $14,327	-546 Reduced 2.08%	25,655 $543,000
Q3 2021 Nov 12, 2021	BUY	$18.65 - $25.46 $21,913 - $29,915	1,175 Added 4.7%	26,201 $586,000
Q2 2021 Aug 05, 2021	BUY	$24.81 - $32.35 $282,238 - $368,013	11,376 Added 83.34%	25,026 $621,000
Q1 2021 May 06, 2021	SELL	$24.04 - $34.19 $18,030 - $25,642	-750 Reduced 5.21%	13,650 $396,000
Q4 2020 Feb 10, 2021	BUY	$25.12 - $29.89 $31,902 - $37,960	1,270 Added 9.67%	14,400 $372,000
Q3 2020 Nov 12, 2020	BUY	$30.79 - $39.92 $51,850 - $67,225	1,684 Added 14.71%	13,130 $404,000
Q2 2020 Aug 13, 2020	BUY	$19.25 - $26.76 $220,335 - $306,294	11,446 New	11,446 $285,000

Others Institutions Holding AKRO

# of Institutions

296

Shares Held

92.2M

Call Options Held

1.72M

Put Options Held

901K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.16B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Akero Therapeutics, Inc. Transaction History